236 related articles for article (PubMed ID: 12387732)
21. Clinical protocol for monitoring of targeted therapies in rheumatoid arthritis.
Geborek P; Saxne T
Rheumatology (Oxford); 2000 Oct; 39(10):1159-61. PubMed ID: 11035144
[No Abstract] [Full Text] [Related]
22. [Economic evaluation of a new treatment for rheumatoid arthritis].
Suka M; Yoshida K
Nihon Rinsho; 2007 Jul; 65(7):1327-30. PubMed ID: 17642251
[TBL] [Abstract][Full Text] [Related]
23. The number needed to treat for adalimumab, etanercept, and infliximab based on ACR50 response in three randomized controlled trials on established rheumatoid arthritis: a systematic literature review.
Kristensen LE; Christensen R; Bliddal H; Geborek P; Danneskiold-Samsøe B; Saxne T
Scand J Rheumatol; 2007; 36(6):411-7. PubMed ID: 18092260
[TBL] [Abstract][Full Text] [Related]
24. Anti-TNF agents for rheumatoid arthritis.
Seymour HE; Worsley A; Smith JM; Thomas SH
Br J Clin Pharmacol; 2001 Mar; 51(3):201-8. PubMed ID: 11298065
[TBL] [Abstract][Full Text] [Related]
25. Cost per treated patient for etanercept, adalimumab, and infliximab across adult indications: a claims analysis.
Bonafede MM; Gandra SR; Watson C; Princic N; Fox KM
Adv Ther; 2012 Mar; 29(3):234-48. PubMed ID: 22411424
[TBL] [Abstract][Full Text] [Related]
26. Biological disease modifying anti-rheumatic drugs.
Cranwell-Bruce LA
Medsurg Nurs; 2011; 20(3):147-50. PubMed ID: 21786492
[No Abstract] [Full Text] [Related]
27. Comparison between adalimumab, etanercept, and infliximab in rheumatoid arthritis: comment on the article by Hetland et al.
Francis S; Block MJ
Arthritis Rheum; 2010 Sep; 62(9):2826; author reply 2826-8. PubMed ID: 20556822
[No Abstract] [Full Text] [Related]
28. Efficacy of treatment intensification with adalimumab, etanercept and infliximab in rheumatoid arthritis: a systematic review of cohort studies with focus on dose.
Eng G; Stoltenberg MB; Szkudlarek M; Bouchelouche PN; Christensen R; Bliddal H; Marie Bartels E
Semin Arthritis Rheum; 2013 Oct; 43(2):144-51. PubMed ID: 23838092
[TBL] [Abstract][Full Text] [Related]
29. Efficacy of low-dose etanercept (25 mg/week): how much do we know?
Berthelot JM
Joint Bone Spine; 2012 Jul; 79(4):335-7. PubMed ID: 22480747
[No Abstract] [Full Text] [Related]
30. Differences in annual medication costs and rates of dosage increase between tumor necrosis factor-antagonist therapies for rheumatoid arthritis in a managed care population.
Ollendorf DA; Klingman D; Hazard E; Ray S
Clin Ther; 2009 Apr; 31(4):825-35. PubMed ID: 19446156
[TBL] [Abstract][Full Text] [Related]
31. [Anti-TNF alpha agents in patients with rheumatoid arthritis refractory to conventional therapies].
González-Gay MA; Agudo M
Med Clin (Barc); 2010 May; 134(15):684-5. PubMed ID: 20176386
[No Abstract] [Full Text] [Related]
32. Cost-effectiveness simulation model of biologic strategies for treating to target rheumatoid arthritis in Germany.
Beresniak A; Baerwald C; Zeidler H; Krüger K; Neubauer AS; Dupont D; Merkesdal S
Clin Exp Rheumatol; 2013; 31(3):400-8. PubMed ID: 23464803
[TBL] [Abstract][Full Text] [Related]
33. [Should we be afraid of the anti-TNFalpha drugs in 2008?].
Gaudin P
Rev Med Interne; 2008 Dec; 29(12):971-4. PubMed ID: 18571291
[No Abstract] [Full Text] [Related]
34. [Efficacy and safety of TNF inhibitors--results of randomized, controlled clinical trials vs long term observational studies].
Filipowicz-Sosnowska A; Kwiatkowska B
Pol Arch Med Wewn; 2006 Oct; 116(4):980-7. PubMed ID: 18416301
[No Abstract] [Full Text] [Related]
35. Cost-effectiveness of sequential therapy with tumor necrosis factor antagonists in early rheumatoid arthritis.
Davies A; Cifaldi MA; Segurado OG; Weisman MH
J Rheumatol; 2009 Jan; 36(1):16-26. PubMed ID: 19012363
[TBL] [Abstract][Full Text] [Related]
36. Adalimumab in rheumatoid arthritis after failed infliximab and/or etanercept therapy: experience with 18 patients.
Brocq O; Albert C; Roux C; Gerard D; Breuil V; Ziegler LE
Joint Bone Spine; 2004 Nov; 71(6):601-3. PubMed ID: 15589452
[No Abstract] [Full Text] [Related]
37. Matching-adjusted indirect comparison of adalimumab vs etanercept and infliximab for the treatment of psoriatic arthritis.
Kirson NY; Rao S; Birnbaum HG; Kantor E; Wei RS; Cifaldi M
J Med Econ; 2013; 16(4):479-89. PubMed ID: 23339434
[TBL] [Abstract][Full Text] [Related]
38. Questions and answers in 2008 about biologics in rheumatoid arthritis.
Weinblatt ME
J Rheumatol; 2008 Sep; 35(9):1878-81. PubMed ID: 18785296
[No Abstract] [Full Text] [Related]
39. No evidence-based practice by biased information from systematic reviews: the case of etanercept and infliximab for the treatment of psoriatic arthritis.
Corrao S; Puleo A; Pistone G; Calvo L; Scaglione R; Licata G
Clin Exp Rheumatol; 2008; 26(1):164; author reply 165. PubMed ID: 18328174
[No Abstract] [Full Text] [Related]
40. Dosing patterns and costs of tumor necrosis factor inhibitor use for rheumatoid arthritis.
Harrison DJ; Huang X; Globe D
Am J Health Syst Pharm; 2010 Aug; 67(15):1281-7. PubMed ID: 20651319
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
